Literature DB >> 9478952

Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits.

M Sugano1, N Makino, S Sawada, S Otsuka, M Watanabe, H Okamoto, M Kamada, A Mizushima.   

Abstract

Cholesteryl ester transfer protein (CETP) is the enzyme that facilitates the transfer of cholesteryl ester from high density lipoprotein (HDL) to apolipoprotein B (apoB)-containing lipoproteins. However, the exact role of CETP in the development of atherosclerosis has not been determined. In the present study, we examined the effect of the suppression of increased plasma CETP by intravenous injection with antisense oligodeoxynucleotides (ODNs) against CETP targeted to the liver on the development of atherosclerosis in rabbits fed a cholesterol diet. The ODNs against rabbit CETP were coupled to asialoglycoprotein (ASOR) carrier molecules, which serve as an important method to regulate liver gene expression. Twenty-two male Japanese White rabbits were used in the experiment. Eighteen animals were fed a standard rabbit chow supplemented with 0.3% cholesterol throughout the experiment for 16 weeks. At 8 weeks, they were divided into three groups (six animals in each group), among which the plasma total and HDL cholesterol concentrations did not significantly change. The control group received nothing, the sense group were injected with the sense ODNs complex, and the antisense group were injected with the antisense ODNs complex, respectively, for subsequent 8 weeks. ASOR. poly(L-lysine) ODNs complex were injected via the ear veins twice a week. Four animals were fed a standard rabbit diet for 16 weeks. The total cholesterol concentrations and the CETP mass in the animals injected with antisense ODNs were all significantly decreased in 12 and 16 weeks compared with those injected with sense ODNs and the control animals. The HDL cholesterol concentrations measured by the precipitation assay did not significantly change among the groups fed a cholesterol diet, and triglyceride concentrations did not significantly change in the four groups. However, at the end of the study, when the HDL cholesterol concentrations were measured after the isolation by ultracentrifugation and a column chromotography, they were significantly higher in the animals injected with antisense ODNs than in the animals injected with sense ODNs and in the control animals. A reduction of CETP mRNA and an increase of LDL receptor mRNA in the liver were observed in the animals injected with antisense ODNs compared with those injected with sense ODNs and the control animals. Aortic cholesterol contents and the aortic percentage lesion to total surface area were significantly lower in the animals injected with antisense ODNs than in the animals injected with sense ODNs and in the control animals. These findings showed for the first time that suppression of increased plasma CETP by the injection with antisense ODNs against CETP coupled to ASOR carrier molecules targeted to the liver could thus inhibit the atherosclerosis possibly by decreasing the plasma LDL + very low density lipoprotein (VLDL) cholesterol in cholesterol-fed rabbits.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9478952     DOI: 10.1074/jbc.273.9.5033

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

Review 1.  Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides.

Authors:  R L Juliano; S Alahari; H Yoo; R Kole; M Cho
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

2.  Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo.

Authors:  E A Biessen; H Vietsch; E T Rump; K Fluiter; J Kuiper; M K Bijsterbosch; T J van Berkel
Journal:  Biochem J       Date:  1999-06-15       Impact factor: 3.857

3.  Biochemical characterization of cholesteryl ester transfer protein inhibitors.

Authors:  Mollie Ranalletta; Kathleen K Bierilo; Ying Chen; Denise Milot; Qing Chen; Elaine Tung; Caroline Houde; Nadine H Elowe; Margarita Garcia-Calvo; Gene Porter; Suzanne Eveland; Betsy Frantz-Wattley; Mike Kavana; George Addona; Peter Sinclair; Carl Sparrow; Edward A O'Neill; Ken S Koblan; Ayesha Sitlani; Brian Hubbard; Timothy S Fisher
Journal:  J Lipid Res       Date:  2010-05-10       Impact factor: 5.922

4.  The inhibition of cholesteryl ester transfer protein: a long and winding road.

Authors:  Kerry-Anne Rye; Philip J Barter
Journal:  J Lipid Res       Date:  2012-04-10       Impact factor: 5.922

Review 5.  The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?

Authors:  Menno Vergeer; Adriaan G Holleboom; John J P Kastelein; Jan Albert Kuivenhoven
Journal:  J Lipid Res       Date:  2010-04-06       Impact factor: 5.922

Review 6.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

7.  Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure.

Authors:  Guoqing Cao; Thomas P Beyer; Youyan Zhang; Robert J Schmidt; Yan Q Chen; Sandra L Cockerham; Karen M Zimmerman; Sotirios K Karathanasis; Ellen A Cannady; Todd Fields; Nathan B Mantlo
Journal:  J Lipid Res       Date:  2011-09-25       Impact factor: 5.922

Review 8.  Raising high-density lipoprotein cholesterol: innovative strategies against an old adversary.

Authors:  Dhruv Kazi; John A Farmer
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

9.  Complex genetic architecture revealed by analysis of high-density lipoprotein cholesterol in chromosome substitution strains and F2 crosses.

Authors:  Ioannis M Stylianou; Shirng-Wern Tsaih; Keith DiPetrillo; Naoki Ishimori; Renhua Li; Beverly Paigen; Gary Churchill
Journal:  Genetics       Date:  2006-09-01       Impact factor: 4.562

10.  Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice.

Authors:  Thomas Gautier; David Masson; Miek C Jong; Jean-Paul Pais de Barros; Linda Duverneuil; Naig Le Guern; Valérie Deckert; Laure Dumont; Amandine Bataille; Zoulika Zak; Xian-Cheng Jiang; Louis M Havekes; Laurent Lagrost
Journal:  Biochem J       Date:  2005-01-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.